RituxiMab INDuction in Renal Transplantation

Recruitment status:
Primary Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Recruitment countries:
United Kingdom
Health condition studied:
Function of Renal Transplant
Link to the clinical trial website

About the trial

Drug: Hydrocortisone
Drug: Mycophenylate mofetil
Drug: Prednisolone
Drug: Rituximab
Drug: Tacrolimus
Key inclusion and exclusion criteria:

  • Inclusion Criteria:

    - Adult patients over 18 years receiving their first living donor renal transplant, or
    their second if the first was not lost from acute rejection

    - Patients who have given written informed consent

    - Women of child bearing potential taking adequate contraception.

    Exclusion Criteria:

    - Previous other organ transplants lost through acute rejection

    - Patients undergoing antibody incompatible transplantation

    - Patients with other organ transplants

    - Patients previously treated with cyclophosphamide, ATG, OKT3 or rituximab

    - Patients with white cell count below 4.0x10^9/L.

    - Patients with platelet count below 100x10^9/L

    - Patients who are treated with drugs that are strong inhibitors or inducers of
    cytochrome P450, or treated with terfenadine, astemizole, cisapride or lovastatin

    - Patients who have been involved in any other investigational trial or non protocol
    immunosuppressive regimen in the previous 90 days prior to transplant

    - Pregnant or breastfeeding women

    - Patients with a documented history of malignancy and its origins and treatment in the
    last five years. (Localised basal cell carcinoma of the skin is permitted)

    - Patients known to be HIV, Hepatitis B surface antigen or Hepatitis C antibody

    - Patients who in the opinion of the Investigator would not be a suitable candidate for
    study participation

    - Women of child bearing potential not willing to take adequate contraception
  • Age minimum:  18 Years
  • Age maximum:  N/A
  • Gender:  Both
Primary outcomes:
Estimated GFR (calculated using the Cockcroft-Gault formula)
Secondary outcomes:
Allograft survival
Biopsy proven acute rejection (based on Banff classification)
Changes in B and T cell repertoire
Infection rate
Patient Survival
Target sample size:
Study type:
Study design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Name:   Nizam Mamode, MD FRCS(Gen)
  • Address: 
  • Phone: 
  • Email: 
  • Affiliation:  Guy's and St Thomas' NHS Foundation Trust
  • Name:   Nizam Mamode, MD FRCS(Gen)
  • Address: 
  • Phone:  +44 20 7188 1543
  • Email:  nizam.mamode@gstt.nhs.uk
  • Affiliation: 

Technical details

Scientific title:
A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation
Sources of monetary support:
Please refer to primary and secondary sponsors
Secondary sponsors:
Astellas Pharma Europe Ltd.
Main ID:
Secondary ID:
Date of registration:
Date of first enrollment:
November 2010
Last refreshed:
23 March 2015


Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record

Back to clinical trials list